LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Allogeneic Stem Cell Transplants Improve Microbiome, Immune Cells

By LabMedica International staff writers
Posted on 30 May 2022
Image: Stem cell transplants are standard of care for cancers such as leukemia, and lymphoma. MAIT and Vδ2 unconventional T cells are supported by a diverse intestinal microbiome (Photo courtesy of Cancer Treatment Centers of America)
Image: Stem cell transplants are standard of care for cancers such as leukemia, and lymphoma. MAIT and Vδ2 unconventional T cells are supported by a diverse intestinal microbiome (Photo courtesy of Cancer Treatment Centers of America)

Past studies have suggested ties between microbial diversity and favorable allogeneic hematopoietic stem cell transplantation (allo-HCT) outcomes, or transplants involving stem cells from healthy donors. The interactions between the gut microbial community and the immune system can influence an individual's response to a bone marrow transplant to treat leukemia, lymphoma, multiple myeloma, and other blood conditions.

It has been reported that a diverse intestinal microbiome at early times after allo-HCT is associated with higher numbers of innate-like mucosal-associated invariant T (MAIT) cells, and this correlated with a higher prevalence of the Vδ2 subpopulation of γδ T cells and a reduced incidence of acute graft-versus-host disease (aGVHD).

A large team of clinical scientists led by the Weill Cornell Medical College (New York, NY, USA) used targeted 16S ribosomal RNA sequencing on fecal samples, as well as flow cytometry-based immune cell profiling in peripheral blood samples, and searched for outcome-related features in 174 allo-HCT recipients. The analyses pointed to an uptick in mucosal-associated invariant T (MAIT) immune cells in individuals with lower rates of acute graft-versus-host disease complications, better stem cell transplant outcomes, and increased survival times.

Immune profiling of conventional and unconventional immune cell subsets revealed that the prevalence of Vδ2 cells, the major circulating subpopulation of γδ T cells, closely correlated with the frequency of MAIT cells and was associated with less aGVHD. Analysis of these populations using both single-cell transcriptomics and flow cytometry suggested a shift toward activated phenotypes and a gain of cytotoxic and effector functions after transplantation.

Among other gut microbial ties, the team found that higher-than-usual MAIT levels in blood samples from the allo-HCT recipients tended to correspond with the presence of gut bacteria from the Bacteroidetes phylum, while decreased blood levels of the T cells turned up in those with Firmicutes-rich gut microbiomes. A diverse intestinal microbiome with the capacity to produce activating ligands for MAIT and Vδ2 cells appeared to be necessary for the maintenance of these populations after allo-HCT. These data suggest an immunological link between intestinal microbial diversity, microbe-derived ligands, and maintenance of unconventional T cells.

Kate Markey, MBBS, PhD, FRACP, an Immunologist and co-senior author of the study, said, “There is a growing awareness in the transplant field that a healthy, diverse microbiome is linked with good outcome. Ways to prevent damage and restore a healthy microbiome are both going to be important and are the subject of active clinical trials now. The study was published on May 25, 2022 in the journal Science Translational Medicine.

Related Links:
Weill Cornell Medical College 

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Gold Member
Collection and Transport System
PurSafe Plus®

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more